Back to top
more

Mustang Bio (MBIO)

(Delayed Data from NSDQ)

$0.35 USD

0.35
55,217

+0.01 (3.34%)

Updated Apr 22, 2024 11:48 AM ET

After-Market: $0.34 -0.01 (-3.68%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Mustang Bio, Inc. [MBIO]

Reports for Purchase

Showing records 1 - 20 ( 51 total )

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

12/11/2023

Company Report

Pages: 10

MB-106 Thesis Continues to Strengthen at ASH; Phase 2 WM Trial Set for Mid-2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/15/2023

Company Report

Pages: 9

3Q23 Results; Additional MB-106 Phase 1/2 Data at ASH, and More Indications Under the Radar

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

08/16/2023

Daily Note

Pages: 7

Initial Phase 1/2 MB-106 Data Show Encouraging Clinical Responses; Further Dose Escalation Expected by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/15/2023

Company Report

Pages: 9

2Q23 Results; Efforts Concentrated on MB-106 Advancement; Several Data Readouts in 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

06/16/2023

Company Report

Pages: 8

MB-106 is On a Roll; High Reponse Rates Impress in Follicular Lymphoma

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

06/12/2023

Company Report

Pages: 7

MB-106''s Antitumor Profile Continues to Mature Following Trial Update at EHA ''23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/23/2023

Company Report

Pages: 6

Strategic Regrouping Places Key Emphasis on MB-106; Price Target Adjusted to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/15/2023

Company Report

Pages: 9

1Q23 Results; Expecting MB-106 To Shine at EHA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/30/2023

Company Report

Pages: 9

2022 Results; Plentiful Data Readouts and Clinical Updates Expected in the Year to Come

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

12/19/2022

Company Report

Pages: 10

Initial MB-106 Phase 1/2 Data and MB-109 IND Filing At the Top of the List For a Fruitful 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/15/2022

Company Report

Pages: 10

3Q22 Results; MB-106 Solidifying Starring Role in Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/12/2022

Company Report

Pages: 10

2Q22 Results; Clinical Programs Raring To Go; Multicenter Phase 1/2 Trial of MB-106 Expected to Start Shortly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/27/2022

Daily Note

Pages: 7

First Patient Treated in Europe in Phase 1/2 Study of MB-110 for RAG1-SCID

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

06/14/2022

Company Report

Pages: 9

MB-106''s Efficacy in r/r Follicular Lymphoma Continues to Impress at EHA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/20/2022

Company Report

Pages: 8

Safe and Sound; Updated Phase 1/2 Data Open Doors For MB-107 Pivotal Phase 2 Trial in XSCID

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/13/2022

Company Report

Pages: 8

1Q22 Results; Data Keep Coming; Key Clinical Updates Continue at EHA for MB-106

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

04/25/2022

Daily Note

Pages: 5

MB-106''s Efficacy in Hematologic Malignancies Continues to Impress; Company-Led Phase 1/2 Set to Begin This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/19/2022

Industry Report

Pages: 7

Gene Therapy Conference; We Think Sentiment Starting to Improve

Provider: H.C. Wainwright & Co., Inc.

Analyst: BRANCHETTI E

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

04/13/2022

Daily Note

Pages: 7

Independent Phase 1 Data Support the Initiation of MB-109’s Clinical Evaluation in GBM

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Mustang Bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/24/2022

Company Report

Pages: 8

2021 Results; Gene and Cell Therapy Trial Initiations and Data Updates Set the Stage for the Year Ahead.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party